In contrast to conventional chemotherapeutic agents which also deplete T effector cells and may induce autoimmunity due to the systemic elimination of T-regs (225), CXCR4 targeting allows the specific targeting of Tregs, since intratumoral Tregs consistently express higher CXCR4 levels than CD4+CD25− and CD8+ cells (226). This evidence concerns the gene CXCR4 and Autoimmunity.